KMLE
»çÀÌÆ® ¼Ò°³
°Ë»ö
°Ë»ö¾î Áö¿ì±â
´Ý±â
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
°í±Þ °Ë»ö ¼³Á¤
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú :
8
ÆäÀÌÁö:
14
Á¦Ç°¸í
¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
ŸÀ̶ó´ÑÁÖ200mg
Teicoplanin 200 mg, Water For Injection 3 mL
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
13301¿ø/1 °³
µð¹Ù¸£ÅºÁ¤160mg
Valsartan 160 mg
ȯÀÎÁ¦¾à
Àü¹®
µð¸àŸ¹Î¼¹æÄ¸½¶8mg
Galantamine Hydrobromide 10.25 mg
ȯÀÎÁ¦¾à
Àü¹®
¶ö·ÎÆæÁ¤
Raloxifene HCl 60 mg
ȯÀÎÁ¦¾à
Àü¹®
¼¼ÆÄ¸Þ·ÒÁÖ1g
Cefpirome Sulfate 1 g
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
5671¿ø/1 °³
¼¼ÆÄ·ÎźÁÖ500mg
Cefotetan 500 mg
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
3432¿ø/1 °³
¼¼ÇÁ¸Þ¸°ÁÖ1g
Cefminox Sodium 1 g
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
3789¿ø/1 °³
¼¼ÇÁ¸Þ¸°ÁÖ0.5g
Cefminox Sodium 500 mg
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
3363¿ø/1 °³
ÀÌÀü
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
gastropathy
À§º´Áõ, À§Áúȯ
gastrosia
À§Áúȯ
gastrosia fungosa
Áø±ÕÀ§º´, °õÆÎÀÌÀ§Áúȯ
gene conversion
À¯ÀüÀÚÀüȯ
gene replacement
À¯ÀüÀÚ±³È¯
genetic disorder
À¯ÀüÁúȯ
geographical pathology
Áö¸®º´¸®ÇÐ, ±âÈÄȯ°æº´¸®ÇÐ
geomedicine
±âÈÄȯ°æÀÇÇÐ, Áö¸®ÀÇÇÐ
geopathology
±âÈÄȯ°æº´¸®ÇÐ, Áö¸®º´¸®ÇÐ
gerontoxon
³ë³âȯ
globulus
1. ȯ¾à 2. °ø, ±¸Ã¼ 3. µ¢¾î¸®
glomerular disease
Å丮º´, »ç±¸Ã¼Áúȯ
gustatory hallucination
¹Ì°¢È¯°¢, ȯ¹Ì
gas exchange ratio
°¡½º±³È¯ºñÀ²
hyperkinemia
¼øÈ¯Ç÷·ù·®°ú´Ù
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
intercurrent disease
º´¹ßÁúȯ
intestinal motility disorder
âÀڿÀå¾Ö, Àå¿îµ¿Áúȯ
ischemic heart disease
ÇãÇ÷½ÉÀåÁúȯ, ÇãÇ÷½ÉÀ庴
liver disease
°£º´, °£Áúȯ
lymphoproliferative disorder
¸²ÇÁ¼¼Æ÷Áõ½ÄÁúȯ
malabsorptive disorder
Èí¼öÀå¾ÖÁúȯ
mendelian disorder
¸àµ¨À¯ÀüÁúȯ
metabolic disease
´ë»çº´, ´ë»çÁúȯ
multifactorial genetic disorder
´ÙÀμºÀ¯ÀüÀå¾Ö, ´ÙÀμºÀ¯ÀüÁúȯ
myelodysplastic disorder
°ñ¼öÇü¼ºÀÌ»óÁúȯ
myeloproliferative disorder
°ñ¼öÁõ½ÄÁúȯ
neurological disorder
½Å°æ°èÀå¾Ö, ½Å°æ°èÁúȯ
neuromuscular disorder
½Å°æ±ÙÀ°Àå¾Ö, ½Å°æ±ÙÀ°Áúȯ
occlusive cerebrovascular disease
Æó¼â³úÇ÷°üÁúȯ
oneiric delirium
¸ùȯ¼¶¸Á
ÀÌÀü
´ÙÀ½
Sponsored Links
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
glutathione reductase deficiency
±Û·çŸƼ¿Â ȯ¿øÈ¿¼Ò °áÇÌÁõ.
glycogen storage disease
±Û¸®ÄÚ°ÕÃàÀû Áúȯ.
glycogen storage disease
´ç¿ø ÃàÀûÁúȯ(ÓØê«õëîÝòðü´)
glycogen storage disease
±Û¸®ÄÚ°ÕÃàÀûÁúȯ
glyoxylate reductase
±Û¸®¿Á½Ç»êȯ¿øÈ¿¼Ò.
gold foil annealing tray
±Ý¹Ú¼Òȯ±â(ÐÝÚØáÀü½Ðï).
gonococcal epididymitis
ÀÓ±Õ¼º ºÎ°íȯ¿°.
graft versus host disease
´ë¼÷ÁÖÀÌ½ÄÆíÁúȯ
granulomatous disease
À°¾ÆÁ¾¼º Áúȯ.
granulomatous disease
À°¾ÆÁ¾¼º Áúȯ
granulomatous disease of childhood
¼Ò¾ÆÀ°¾ÆÁ¾¼º Áúȯ.
granulomatous disease of childhood
¼Ò¾Æ À°¾ÆÁ¾¼º Áúȯ
grater circulation
´ë¼øÈ¯.
greater circulation
´ë¼øÈ¯(ÓÞâàü»).
gubernacular canal
°íȯµµ´ë°ü(°íȯµµ´ë°ü).
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
15
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
case finding
ȯÀÚ¹ß°ß (ü´íºÛ¡úæ), Áõ·Ê¹ß°ß.
case finding program
ȯÀڹ߰߰èȹ, ȯÀڹ߰߻ç¾÷.
air ambulance
ȯÀÚ¼ö¼ÛºñÇà±â.
sickroel behavior
ȯÀÚ¿ªÇÒÇàÅÂ.
stretcher
ȯÀÚ¿î¹ÝÂ÷.[Á¤Çü]µé°Í, ½ÅÀå±â.
patient positioning
ȯÀÚÀ§Ä¡°áÁ¤
patient triggered respirator
ȯÀÚÀ¯¹ß½ÄÀΰøÈ£Èí±â.
patient triggered ventilator
ȯÀÚÀ¯¹ßÈ£Èí±â(ü´íºë¯Û¡û¼ýåÐï).
informed consent
ȯÀÚÀÇ µ¿ÀÇ, ½Â³«
patient position
ȯÀÚÀÇ ÀÚ¼¼
complaints of patient
ȯÀÚÀÇ È£¼Ò(ü´íº¡û¼áÍ).
patient preparation
ȯÀÚÁغñ
patient evaluation
ȯÀÚÆò°¡
patient identification
ȯÀÚÈ®ÀÎ
patient performance index
ȯÀÚȰµ¿°è¼ö
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
biliary cycle
´ãÁó ¼øÈ¯(¡¼øÈ¯).
biliary cycle
´ãÁó ¼øÈ¯(¡âàü»)
biliary tract disease
´ãµµÁúȯ
bioreductive agent
»ýüȯ¿ø¹°Áú
bioreductive drug
»ýüȯ¿ø¼º¾àÁ¦, -¾à¹°
biosphere
´ë»ýȰ±Ç, »ý¹°È¯°æ¹ÝÀÀ±Ç, »ý¹°±Ç(ßæÚªÏê).
biosphere
´ë»ýȰ±Ç, »ý¹°È¯°æ¹ÝÀÀ±Ç, »ý¹°±Ç(Ë×ËÑË´).
biotransformation
»ýüº¯È<º¯È¯>(¡Ü¨ûù<ܨüµ>).
biotransformation
»ýü³»º¯È<º¯È¯>(¡Ò®Ü¨ûù<ܨüµ>)
biotransformation
»ýü³»º¯È¯.
bissa
ºñ½Î ¡ìÀÌÁýÆ® ºÎÁ¾¼º Áúȯ¡í.
bladder replacement
¹æ±¤Ä¡È¯(¼ú)
blistering(bullous) disease
¼öÆ÷¼ºÁúȯ(¡òðü´)
blood circulation
Ç÷¾×¼øÈ¯(úìäûâàü»).
blood disease
Ç÷¾×Áúȯ
ÀÌÀü
´ÙÀ½
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú :
5
ÆäÀÌÁö:
14
ÄÚµå
¿µ¹®
ÇѱÛ
C62.1
Descended testis
Çϰ °íȯ
C62.9
Testis, unspecified
»ó¼¼ºÒ¸íÀÇ °íȯ
C63.0
Epididymis
ºÎ°íȯ
C88
Malignant immunoproliferative diseases
¾Ç¼º ¸é¿ªÁõ½Ä¼º Áúȯ
C88.7
Other malignant immunoproliferative diseases
±âŸ ¾Ç¼º ¸é¿ªÁõ½Ä¼º Áúȯ
ÀÌÀü
´ÙÀ½
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
¼³¸í
malum
Áúȯ, Áúº´
manual reposition
¿ë¼ö ȯ³³¹ý, ¿ë¼ö Á¤º¹
margo anterior testis
°íȯ Àü¿¬
Á¤¼ÒÀÇ µÕ±Ù ÀÚÀ¯ ¿¬.
massa lateralis atlantis
ȯÃß ¿ÜÃø ±«
ȯÃß°ñ ¿ÜÃø µ¢ÀÌ.
matrix band
°Ýº® ¹êµå, ȯ»ó °Ýº®
1. 2±Þ ¿Íµ¿ ÃæÀü ½Ã »ó½ÇµÈ ÀÎÁ¢ ¸é¸¦ ´ë½ÅÇϱâ À§ÇØ ÃæÀü¹° ÃæÀü¿¡ »ç¿ëÇÏ´Â ¹êµå. 2. ¿Íµ¿ Áß¿¡ ¾Æ¸»°¨À» ÃæºÐÈ÷ Àü»öÇϱâ À§ÇÏ¿©, ¶Ç´Â º¹À⠿͵¿ÀÇ °á¼Õ º®À» ä¿ì±â À§ÇÏ¿© Ä¡¾Æ µÑ·¹¿¡ ºÙÀÎ ¾ãÀº ±Ý¼Ó Æí.
medical ICU
³»°ú°è ÁßȯÀÚ½Ç
melancholiac
¿ïº´ ȯÀÚ, ¿ì¿ïÁú
membrana atlanto-occipitalis posterior
ÈÄȯÃß Èĵθ·, µÚ°í¸® µÚÅë¼ö ¸·, µÚȯÃß Èĵθ·
ȯÃßÀÇ Èıÿ¡¼ ÀüµÎ°ñÀÇ ÈĹæ°è¸¦ Áö³ª°í, À§Ä¡ÀûÀ¸·Î Ȳ»ö Àδ뿡 ´ëÀÀÇÏ´Â ´ÜÀÏÀÇ Á¤Áߺο¡ ÀÖ´Â ÀÎ´ë ±¸Á¶.
micro-orchidism
¼Ò°íȯÁõ
°íȯÀÌ ºñÁ¤»óÀûÀ¸·Î ÀÛÀº °Í.
microrchidia
¼Ò°íȯÁõ
°íȯÀÌ Á¤»ó ÀÌÇÏ·Î ÀÛÀº °Í.
milieu
ȯ°æ
mini annular phased array
¼Ò ȯ»ó À§»ó ¹è¿
modulation
º¯Á¶, Á¶Á¤, Á¶Àý, ȯ°æ ÀûÀÀ´É, ÀüÇü
ȯ°æ¿¡ ´ëÇÑ ¼¼Æ÷ ÀûÀÀ¼ºÀÇ Á¤»ó ´É·Â.
monocyclic
´ÜȯÀÇ
monorchidism
´Ü °íȯ, ´Ü °íȯÁõ
µ¿ÀǾî=monorchism.
ÀÌÀü
´ÙÀ½
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú:
10
ÆäÀÌÁö:
14
Æä·ÎÁ¬ÁÖ
A09703941
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Sodium ferric gluconate complex
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | »èÁ¦
¸ÞŸµ¥ÀÌÆ®CD¼¹æÄ¸½¶
G02500021
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Methylphenidate HCl
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ±Þ¿©
½É¹Ù½º·ÎÅØ
A09703971
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Simvastatin
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ±Þ¿©
Æç¸®½ºÄ¸½¶
A09703901
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: »óȲ±Õ»çü¿¢½º
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ±Þ¿©
¹Ù·ùÁ¦ÆÊÁÖ
G01000231
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Nalbuphine HCl
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | »èÁ¦
¸®Æä¸®µ·Á¤0.5mg
A09704001
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Risperidone
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ±Þ¿©
´º·¾Åçĸ½¶300mg
A09703981
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Gabapentin
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ±Þ¿©
À¯¶õŹÁ¤75mg
A09751051
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Ranitidine HCl
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ±Þ¿©
´ÙÀÌÇǸ±Á¤2mg
A09703991
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Glimepiride
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ±Þ¿©
´º·¾Åçĸ½¶100mg
A09704041
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Gabapentin
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ±Þ¿©
ÀÌÀü
´ÙÀ½
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
bath chair
(ȯÀÚ ¿ÜÃâ¿ëÀÇ)¹ÙÄû ´Þ¸° ÀÇÀÚ
beamy
(Ç×ÇØ)ÆøÀÌ ³ÐÀº;±¤¼±À» ¹æ»çÇÏ´Â;ºû³ª´Â;ȯÇÑ;Áñ°Å¿î;(¼ö»ç½¿ÀÌ)°¡Áö»ÔÀÌ ÀÖ´Â
bedpan
º¯±â;ȯÀÚ¿ë º¯±â
beguilement
±â¸¸;¼ÓÀÓ;±âºÐÀüȯ °Å¸®;½É½ÉÇ®À̰¡ µÇ´Â °Í
beguiling
¼ÓÀÌ´Â;±âºÐÀ» Àüȯ½ÃŰ´Â
belt highway
¼øÈ¯µµ·Î
belt line
¼øÈ¯¼±
beltway
¼øÈ¯µµ·Î
bill
°è»ê¼;¸ñ·Ï;ȯ¾îÀ½;ÀǾÈ-±¤°íÇÏ´Ù;¿¹°íÇÏ´Ù;û±¸¼¸¦ º¸³»´Ù;ºÎ¸®;ºÎ¸®¸¦ ¸Â´ë´Ù
bioenvironmental
»ý¹° ȯ°æÀÇ(»ý¹°ÀÇ È¯°æ°ú ƯÈ÷ ±× ¼ÓÀÇ À¯ÇØ ¿ä¼Ò¿¡ °üÇÑ)
biohazard
»ý¹°ÇÐÀû À§Çè(»ç¶÷°ú ±× ȯ°æ¿¡ ´ëÇØ À§ÇèÀÌ µÇ´Â »ý¹°ÇÐÀû ¹°Áú »óȲ)
biometeorology
»ý¹° ȯ°æÇÐ
biotron
¹ÙÀÌ¿ÀÆ®·Ð(ȯ°æÁ¶°ÇÀ» ÀÎÀ§ÀûÀ¸·Î Á¦¾îÇÏ¿©,±× ¼Ó¿¡¼ »ý¹°À» ±â¸£´Â ÀåÄ¡)
blase
ȯ¶ô¿¡ ÁöÄ£
bleed
ÃâÇ÷ÇÏ´Ù;ÇÇÈ긮´Ù;½½ÆÛÇÏ´Ù-(ȯÀÚÀÇ)ÇǸ¦ »Ì´Ù;µ·À» ¿ì·Á³»´Ù-ÂïÈù ºÎºÐ±îÁöµµ ÀÚ¸¥»çÁø;ÀμâµÈ ºÎºÐ±îÁöµµ ÀÚ¸¥ »çÁø
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
Á¦Ç°¸í
¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
ÀÌÀü
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
ÀÌÀü
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
ÀÌÀü
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
ÇÑÀÚ
ÀÌÀü
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
ÇÑÀÚ
ÀÌÀü
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
ÀÌÀü
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
ÀÌÀü
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
ÀÌÀü
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
ÀÌÀü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
ÀÌÀü
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
ÄÚµå
¿µ¹®
ÇѱÛ
ÀÌÀü
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
¼³¸í
ÀÌÀü
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú:
0
ÆäÀÌÁö:
14
ÀÌÀü
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
14
¿µ¹®
ÇѱÛ
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½